RETN and obesity disorder: Elevated circulating resistin levels observed in obesity and type 2 diabetes mellitus contribute to insulin resistance through inhibition of adenosine monophosphate kinase (AMPK) activity in hepatic and skeletal muscle tissues, thereby disrupting insulin signaling pathways (5).